Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YIAD-0708
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
YIAD-0708 is an experimental compound characterized as a targeted agent for disrupting amyloid-beta 42 (Aβ42) aggregates, a pathological hallmark of Alzheimer's disease. The compound is reported to interact directly with Aβ42 aggregates, disrupting their structural core and potentially converting toxic amyloid species into less harmful forms. Its mechanism of action involves the direct disaggregation of amyloid plaques rather than traditional amyloid-lowering or stabilization strategies. YIAD-0708 is being studied as a disease-modifying therapy in Alzheimer's disease and is at an investigational stage with ongoing preclinical or early clinical research[7].
02
Targets
Aβ42 aggregate (Amyloid-β 42 aggregate)
Beyond the preview
Go deeper on YIAD-0708.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YIAD-0708.